We'll get started here. Matt Stanton on the life science tools diagnostics team. Happy to have GeneDx with us again at the conference this year. Kevin, appreciate you being here today.
Great. Thanks for having us.
Maybe just to kick off, I think maybe just zoom out and we can kind of talk higher level, recap how the year's gone. I think there's been some fits and starts on the genome mix, some ASP, but fundamentally, you're on track to deliver volumes near 30% for the year again this year. Also targeting opportunities to expand sales force, working on RCM. Maybe just talk about kind of where things have gone according to plan, maybe things have exceeded, and where there's been a bit more of a challenge as we move through the year.
Yeah. Thanks for having us. Always a highlight of the year. For those not familiar, GeneDx is a leader in providing genomics services to diagnose children with pediatric rare disease. In doing so, we're serving a large unmet clinical need out there. There's 30 million Americans alone with rare disease. That's one in 10. That's more than the cancer market. In the market strategy we have, it's to continue to move upstream in terms of getting physicians to order testing earlier on in order to end the diagnostic odyssey. In doing so, it means moving to new physician types, and we've embarked on a pretty ambitious plan to move beyond where these tests have resided in the past, which is within a small cohort of about 2,000 expert geneticists, and move into much larger physician and patient populations.
The business, to your point, growing nicely, but throughout the year, a lot of lessons learned. I think what we owe investors, and ourselves frankly, is some more visibility into the business. There is a lot of known unknowns with respect to opening new markets. We have certainly seen some challenges, but when we step back, we have got a business that is growing volumes in the high 20s. It has got a gross margin profile solidified in the 30s. It is profitable. It has been a successful year. We have now seen sequential improvements in the overall business performance from Q1 to Q2 to Q3. Really proud of how the year has progressed, but it fell short of our initial expectations to start the year. Some volatility earlier in the year with respect to mix shift from exome as the leader within the portfolio into genome.
That mix shift dynamic caught us a bit by surprise earlier in the year. It was catalyzed by strong demand out there by geneticists to move into a genome-only world and some competition. But at the end of it, what we have seen is physicians move from exome to genome, but not necessarily leave GeneDx. With that, saw a sharp rise earlier in the year into genome. That has put some pressure on some year-over-year comparisons. But when we take a step back, a move into genome is inherently a very good thing for our business and for the mission that we serve, which is to ultimately end the diagnostic odyssey. When I started at this company 11 years ago, the average age of diagnosis was about 14 years old. We now have it down to about five for children with rare disease.
As we move into the much larger opportunity ahead, which is general pediatricians ordering exome or genome for children with global intellectual developmental delay, confident that through the course of the second half of this decade, we will continue to bring that number closer down to at or around birth.
Okay. Maybe on ASPs, up, I think, mid-single digits sequentially. It was about $100 better than expectations. Just talk about the upside ASP dynamics in 3Q. Was it some of the genome mix you talked about being lower? Was it better collections on those genomes? What drove the sequential ASP improvement? Then I guess, as it relates to 4Q, you are guiding for another sequential uptick of $100. Are those the same drivers? Are there different drivers? Is Carelon coming in more meaningfully? Just kind of unpack both the sequential improvement into 3Q and then what you are underwriting for 4Q here as well.
Yeah. In Q3, both mix and underlying collection rate improvements contributed about equally. I think really pleased to see that the genome collection rate improved from 32% to 36% in the third quarter . What is most exciting about that is we are embarking on a multi-year revenue cycle transformation, one designed to capture more comprehensive, more accurate documentation further upstream in the order-to-result process in order to meet what is a wide array of disparate payer policies and specific documentation requirements. That work ongoing in implementation phase. The step up we have seen just this quarter alone without the much bigger opportunity to get far more payer-specific in terms of our workflows, attribute the improvement just this quarter to. In a word, slow down a bit to ensure that we are properly securing documentation and prior authorization before we begin sequencing of services.
At this point, a bit of manual brute force to do that. There are some more sophisticated ways to ensure that process runs more efficiently in the future. In the third quarter , did put in some of that slowdown with respect to the genome product in order to try to secure higher reimbursement rates.
On 4Q, similar, is any of the Carelon dynamics starting to show up in 4Q, or is that more of a 2027 story?
We began to see strong signals, early signals from payers that do look towards Carelon as lab benefit manager. I would not say the third quarter is fully baked in any of the benefit of that Carelon policy change. It will take several quarters really for it to have a building and stacking effect in the rates that we see. The fourth quarter does count on some incremental benefits in a continuation of that progress, but also continuation of the revenue cycle work to come, we think. In the fourth quarter , we do typically see a seasonal benefit that starts with a Q1 low point in terms of that average reimbursement rate and rises throughout the year.
There's some seasonal uplift to come in the fourth quarter , continuation of the revenue cycle progress, and the majority of policy decisions such as Carelon and additional state Medicaid programs that have picked up policies in the past several quarters.
Okay. Maybe last one on ASP. You guys noted pretty significant improvement in the genome claims submitted to payers with active coverage. I think it was up 15% from, call it high 60s to low 80s. The percent of genome lives covered commercially today is 88%. Do we continue to march up towards 88 over time? Is there anything in terms of a lag effect between when that coverage flows through to the collection rates as well?
Yes, would expect those rates to converge. Ultimately, a revenue cycle process aimed at making sure that we're matching, first and foremost, the test to the correct and appropriate individual clinical circumstance, but then also running tests that meet eligibility and policy criteria. Would expect over time the amount of claims submitted with payers with underlying policies to continue to converge, meaning rise in a bit of sequential fashion until those two numbers match each other. Look, the question of payer policies and covered lives turning into actual cash collections is at the heart of the work that we have to do. It's the most exciting opportunity financially for the business, but it also is one that fundamentally acknowledges that payer policy doesn't equal cash collection.
I think it's incumbent on us, if you look at the overall maturity cycle of where exome and genome fit, these are still fairly nascent technologies in the eyes of payers. Because of that, a wide disparity of medical necessity policy and documentation and eligibility criteria. What we've struggled with is keeping pace with what is effectively close to 1,000 different rule sets across the payer universe, rather than what you might see in a more mature product, say hereditary cancer or some other form of mature test type, where nearly every payer has the same rule set. We're hard at work building the payer intelligence engine to be able to make sure that we're holding claims properly and matching eligibility and documentation requirements.
That is the work that will bridge the gap between what is extraordinary coverage today, both exome and genome, near or above 90% of commercial lives having policy coverage, and the gap between the near one in three cases that we collect on today. As we continue to converge those two closer together, there's a massive opportunity for us to drive revenue uplift so that revenue growth rates can converge back with and eventually exceed volume growth rates, but also drive leverage that falls right to operating margin over time.
Okay. I want to get to the RCM initiatives in a second, but maybe just on the volume piece. Volume's up, I think, 25% in the quarter. You talked about sample accessions were 28%. That was a new metric, the delta, the 3%. Maybe just talk about what drove that, and then going forward, does that converge and narrow? Should that kind of persist at this magnitude for another quarter or two? Just help us kind of think about the toggle between the two and where that kind of goes over time.
Yeah. I've been at the company for a little more than a decade. Those two rates typically track in parallel with each other and in pretty close alignment. The divergence of that 3 percentage points was new this quarter and is a result of the processes that we put in, which, again, fairly manual, to hold samples to ensure that we're seeking prior authorization and have the right documents in order to do so before beginning sequencing to ensure that our date of service aligns with what payers might expect on the timing of us submitting prior authorization. So that's led to an inherent slowdown in the end-to-end order to result process.
Over time, we'd expect those two figures to converge back, but frankly, not until we get to the point of going live with some of the more automated workflows, AI intelligence to scrape medical records to make securing that documentation invisible or fairly frictionless to the physician. So over time, new workflows designed to, yes, help us collect better, but also help us move through those pre-analytical steps more efficiently. As I mentioned on the call, that work is ongoing. Shovels are in the ground. Think of Q4 and Q1 as key implementation periods to be able to come out of and go live with new workflows. At that point, would expect those two rates between accessions and reports to begin to converge back to each other.
Okay. If we zoom back above that, you guys did this kind of deep dive on RCM initiatives that got you to these actions. Maybe just talk about kind of learnings. I think one of the main ones was almost two-thirds of denials are administrative and really had nothing to do with medical necessity. So maybe just zooming up, kind of do a postmortem on the deep dive on the RCM, what you guys learned, and what some of those actions look like that you're undertaking here.
Yeah. The reality is, we've gone through, if you look at the past 12 to 18 months, significant progress in securing more and more payer coverage in terms of policy, an actual step down, step back in collection rates over the last year, with our processes being set up to be fairly one-size-fits-all across payer and manual at that. In a world where technology and AI absolutely can be our friend, we had not, over the past year, prioritized revenue cycle investments where it is now, which is the number one operational imperative for the company. So the biggest lesson learned is in ensuring that we keep pace with respect to the other side of the equation, payers' denial management, and ensuring that we're doing everything to collect documentation further upstream in the process and meeting those payer-by-payer specific requirements. Some are fairly complex.
Some are as simple as individual payers requiring a wet signature on an order form, or evidence that a prior genetic test has been performed for the patient. It's incumbent on us to make sure we get those documentation items in order. The biggest lesson learned is we can't take our eyes and get complacent with an ever-evolving payer landscape on the other end.
Okay. Maybe, I think you guys signaled that the initial focus of some of the RCM was going to be on the genome side. I guess for someone who's not as in the weeds on rare disease, genomic billing, why wouldn't that also benefit exome? Maybe just talk to some of the nuances going at genome first and why some of those would maybe impact the unit economics of one over the other as we think about genome versus exome.
Yeah, it's a great question. The workflows that we're putting in and transformation work will apply equally to all products, whether it's genome, exome, chromosomal microarray, or there's still hundreds of multi-gene panels and single-gene tests on our menu. In the third quarter , as I described, we put in fairly manual brute force controls to collect documentation, to chase physicians for signatures and documentation, and to slow down the process to seek prior authorization before beginning sequencing on the sequencer. That does have a counterbalance of a degraded customer experience. So slowing down and asking physicians to engage in documentation efforts, we'd acknowledge, is a bit of a degraded customer experience in the short term. We think in the long term, the right decision to build and grow a healthy market over time, and one that has an expectation of being paid fairly for services.
If you look at the total portfolio, exome is the majority. About 75% of the exome genome portfolio was exome. Frankly, we have higher gross margins on that product today. So at this point, are accepting absorbing a higher denial rate, but thought it right and appropriate at this point to put in those manual holds for genome. Exome will see the benefit of the broader transformation, which, as I described, is ongoing.
Okay. Then maybe just lastly on collection rates. I think today, 30%-40%, you've talked to, I think, ultimate target of 70%-80%. As you put some of these in, are there any kind of guardrails in terms of cadence or magnitude? Is it a point or two? Is there opportunity for kind of chunkier 5%, 10% improvements? How do we think about bridging the 30 to 40 to the ultimate goal, which will take time, 70 to 80, as you roll some of these out, both magnitude and cadence, that you have line of sight to?
Yeah. As you can imagine, we've spent a lot of time looking at the reasons behind each of those denials mentioned on our earnings call last week. About 62% of all denials are what I'd characterize as front-end administrative procedural. Easy to say in terms of addressable, all comes down to execution. I think the confidence we have in addressing those comes from new leaders that we put in place. We've been able to secure proven talent who's gone through this type of transformation at large scale with companies that you all would recognize. They validated the opportunity, and that includes the long-term ceiling that we framed out, which is a target to achieve a 70%-80% collection rate over time. It's going to take several quarters to get there.
Improvements we fully expect will begin to show up sequentially once we get through the implementation phase this Q4 and into Q1.
Okay. Maybe shifting gears over to general pediatrics. I mean, I think we go back a year ago, this was something we spent a lot of time on. Very exciting opportunity. I think you guys were pretty clear, early days, this will take time. Start to pick up at the back half of this year and more meaningful growth opportunity in 2027 and beyond. Maybe just talk about kind of progression in the last 12 months, what you've kind of seen, and then also just how you're feeling about kind of that improvement into 2027 and beyond for this exciting opportunity.
Yeah. So we went through a sizable commercial expansion earlier in this year, added roughly 50 specialized sales reps for general pediatricians. They hit the field in February, so they have a couple months now to begin to ramp. Happy to say we're seeing in all of our internal indicators in terms of new account activations, and in the third quarter an opportunity for the first time to see what is the rate of general pediatricians who've not just signed an account and ordered once, but what is their repeat order rate? And really pleased with what we're seeing there in terms of physician acumen and uptake. Ultimately, if you look at underlying guidelines from the American Academy of Pediatrics, it came out in 2025. It was 11 years between guideline updates for genetic testing, and it was a big one. It covered, at this point, global intellectual developmental delay.
That's one in six kids in the U.S. It's a massive population that needs to be addressed, but there's a lot of acumen and education building. So for the past couple quarters since hitting the field in February, the team has been focused on just that, ensuring that those guidelines are out there, that they're well understood, and taking forward to that community the earned trust that GeneDx has. 25 years of serving expert clinical geneticists. Eight out of 10 expert geneticists in the U.S. order their exome and genome from GeneDx, and we think that earned trust will serve us as we move into a more nascent market like general pediatricians.
Okay. Do you have enough data yet to tell how much of this is from, call it, a new untapped market versus maybe cases that would have ended up at a geneticist or a neurologist? Do you guys have enough visibility and data to parse out the two as we think about the penetration of this opportunity?
Yeah, I mean, the question of cannibalization is always interesting, and it really speaks to that diagnostic odyssey. There are 2,000 clinical geneticists in the United States. As I said, there are 30 million Americans with rare diseases, one in 10. There is one in six children with global intellectual developmental delay. To reach a point of cannibalizing and putting geneticists out of work is decades, if not my lifetime, out. I think more so what we want to do is honor the time of those expert geneticists for the cases that really require that level of specialization. We have seen analogs in cancer and in other test types moving out of specialists and into more primary care settings further upstream.
The market is large enough that right now what we are focused on doing is evangelizing the use of these tests upstream, eventually moving towards a potential world of genomic newborn screening. Even at that, 3.6 million live births a year, it would take more than a decade to work through a latent population of children who have missed out on a diagnosis. Yes, we think we have visibility, but more so on what is a much larger opportunity ahead.
Okay. That is helpful. Maybe on NICU, I think it has maybe taken a backseat from investors' focus this year, but you have talked about really nice growth, I think above corporate average for that. Maybe just talk about broadly trajectory of that business this year, and then as we think about 2027, is there scope to continue to drive above corporate average type volume for the NICU opportunity?
Yeah, to not be confused, it's maybe, I think you're right, not had as much investor focus, but it certainly does internally. We remain excited and convicted in the NICU market. It's a market I love because it's 100% cash pay, institutional pay, not subject to the whims of adjudication by commercial payers. Overall, continue, and in large part underpinned by the work at Seattle Children's and the SeqFirst study to see a need for about a quarter million tests a year for children in the NICU. Today, utilization rates are mid to high single digits against that. The barriers remain a long sales cycle, multiple constituents within hospital systems, and really finding a way within each hospital system and NICU to embed this into clinical practice and their own protocols. That often takes rewriting SOPs and protocols.
It's a long, arduous task to change some of those procedures and protocols. So, I think if we look at fiscal 2026, as you mentioned accurately, the NICU is growing above the total portfolio average. It's growing nicely. It's not yet hit any inflection point that would say within the next year or two or three, we'll get to that quarter million tests a year out of the NICU, but we remain convinced the clinical need is there and the value proposition is there as well for hospital executives.
Just real quick, just very under-penetrated market, is there a single gating factor to kind of that utilization inflection, or is it kind of a number of things as you think about tapping that under-penetrated market?
I think we're seeing the nuances. I think we're seeing a different answer across each and every hospital system, and really finding out what it will take to make sure that they can implement protocols to serve these families well without causing disruption in what is a high-margin, high-intensity, high-speed department of the hospital system.
Okay. All right, with that, I think we'll leave it there. Thank you, Kevin. Appreciate it.
Great. Thank you.